AIBD – Autoimmune Bullous Diseases
Thematic group
Chairs and Focus
Related Conditions
Participating Reference Centres
- AOU Città della Salute e della Scienza di Torino – Torino
- AOU Padua – Azienda Ospedale Università di Padova
- APHP – Hôpital Necker-Enfants malades
- ASL Tuscan Centre
- CHU de Rouen
- Colentina Clinical Hospital
- EB Haus Austria
- Fondazione Policlinico Universitario A. Gemelli – Roma
- Helsinki University Hospital
- Hospital Na Bulovce
- Hospital of Lithuanian University of Health Sciences Kauno Klinikos
- IRCCS IDI Foundation Luigi Maria Monti – Rome
- Klinikum der Universität München
- Saint Anna University Hospital in Brno
- Spedali Civili di Brescia – Brescia
- Universitätsklinikum Erlangen
- Universitätsklinikum Freiburg – Center for Skin Fragility & Epidermolysis bullosa
- Universitätsklinikum Schleswig-Holstein
- Universitätsklinikum Würzburg
- University Hospital Centre Zagreb
- University Medical Centre Groningen
Dashboard
Legend for guidelines and publications
Clinical Outcome Measures
No public document yet
Emergency Cards
No public document yet
Guidelines & Recommendations
S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology- S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)
European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the EADV – Part II.- Mucous Membrane Pemphigoid guidelines – guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by EADV – Part I.
- Dermatitis herpetiformis guidelines – S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by EADV
- Diagnosis and management of pemphigus: Recommendations of an international panel of experts
- Diagnosis and management of pemphigus
- Validity and reliability of the Chronic Oral Mucosal Diseases Questionnaire in a UK population
- Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the EADV
- Pemphigus S2 Guideline for diagnosis and treatment guided by the European Dermatology Forum in cooperation with the EADV
Patient Documents
- Drugs used in Autoimmune bullous disease
- Information sheet for patients affected by Bullous Pemphigoid
- Information sheet for patients affected by Bullous Pemphigoid – French version
- Information sheet for patients affected by Mucous Membrane Pemhigoids (cicatricial pemphigoid, epidermolysis bullosa acquisita, linear IgA dermatosis with mucosal involvement)
- Information sheet for patients affected by Mucous Membrane Pemhigoids (cicatricial pemphigoid, epidermolysis bullosa acquisita, linear IgA dermatosis with mucosal involvement) – French version
- Information sheet for patients affected by pemphigoid gestationis
- Information sheet for patients affected by pemphigoid gestationis – French version
- Information sheet for patients affected by Pemphigus
- Information sheet for patients affected by Pemphigus – French version
- Patient AIBD VADEMECUM english
- Tips for a salt-free and low sugar diet during general corticosteroid therapy
- Tips for a salt-free and low sugar diet during general corticosteroid therapy – French version
- Tips for the daily life of patients with an autoimmune bullous disease
- Tips for the daily life of patients with an autoimmune bullous disease – French version
- Wound care guidelines – Local skin and mucosal care in pemphigus and pemphigoid / AutoImmune Blistering Diseases (AIBDs)
Publications
- European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II.
- European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I.
- S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)
- Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology
- IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients
- International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid
- Paraneoplastic autoimmune multiorgan syndrome (PAMS)
- Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
- Autoantibody Detection for Diagnosis in Direct Immunofluorescence-Negative Mucous Membrane Pemphigoid: Ocular and Other Sites Compared
- Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic
- Pemphigus
- A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid